Home › Lilly And AstraZeneca Expand Immuno-Oncology Research Collaboration With New Combinations
 

Keywords :   


Lilly And AstraZeneca Expand Immuno-Oncology Research Collaboration With New Combinations

2015-10-26 04:26:54| drugdiscoveryonline News Articles

Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE:AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

Tags: research expand collaboration combinations

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.11 Next%
15.112019 figma
15.11[] 5
15.11!!
15.11S11 NITRO 156cm
15.1115
15.1127.2mm
15.11 35
More »